Roberts David B

Roberts David B, President and Director of LeMaitre Vascular (LMAT), has maintained a consistent sell-side posture in his recent SEC Form 4 filings, with no open-market purchases recorded across his 54 total transactions. The overwhelming majority of his activity centers on LMAT, where he has executed two open-market sales in the past three months: $356,585.81 on March 11, 2026, and $903,957.74 on February 27, 2026. These sales, combined with his broader filing history, bring his total disclosed sell value to approximately $2.26 million, while his buy value stands at zero—a pattern that indicates a clear disposition bias rather than accumulation. The remaining transactions are largely mechanical or compensatory in nature, including option exercises (coded M), share grants (coded A), and shares withheld to cover tax obligations (coded F). Notably, his most recent filings on June 4 and June 7, 2026, consist exclusively of zero-value grants and option exercises, suggesting routine equity compensation rather than discretionary trading. The only non-LMAT activity involves a single option exercise for AVR, also valued at zero, which does not alter the overall picture of a seller reducing his position in the medical device company. While the two open-market sales in late February and mid-March represent the only discretionary transactions in the recent window, they are substantial in size and follow a pattern of periodic liquidation. The absence of any open-market purchases, combined with the recurring sale events, points to an insider who is consistently monetizing equity holdings rather than adding to them. The data does not indicate whether these sales are part of a pre-arranged plan or tied to personal financial planning, but the directional trend is unambiguous: Roberts is a net seller of LMAT shares.